|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
02196 FOSUN PHARMA
Nominal 
15.260 -0.100 (-0.651%) | 2021/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2020/12 RMB(K¥) | 2019/12 RMB(K¥) | 2018/12 RMB(K¥) | 2017/12 RMB(K¥) | |
| Turnover | 38,864,174 | 28.846% | 30,163,260 | 28,389,277 | 24,713,875 | 18,361,608 |
| Cost of Sales | (20,229,785) | 47.302% | (13,733,529) | (11,543,421) | (10,365,309) | (7,608,953) |
| Gross Profit | 18,634,389 | 13.419% | 16,429,731 | 16,845,856 | 14,348,566 | 10,752,655 |
| 2021/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2020/12 RMB(K¥) | 2019/12 RMB(K¥) | 2018/12 RMB(K¥) | 2017/12 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | (74,016) | -29.398% | (104,836) | (97,114) | (27,162) | -- | |
| Profit / (Loss) on Disposal | -- | -- | -- | -- | -- | -- | |
| Other Non-operating Items | -- | -- | -- | -- | -- | -- | |
| Share of Results of Asso. & JCEs | 1,789,137 | 13.213% | 1,580,335 | 1,431,414 | 1,348,997 | 1,351,323 | |
| Profit / (Loss) before Taxation | 6,042,670 | 29.176% | 4,677,846 | 4,525,753 | 3,579,593 | 4,061,717 | |
| Taxation | (1,066,401) | 44.525% | (737,865) | (782,231) | (559,711) | (476,458) | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | (247,558) | -10.683% | (277,168) | (421,904) | (311,959) | (460,759) | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | 4,728,711 | 29.101% | 3,662,813 | 3,321,618 | 2,707,923 | 3,124,500 | |
| 2021/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2020/12 RMB(K¥) | 2019/12 RMB(K¥) | 2018/12 RMB(K¥) | 2017/12 RMB(K¥) | |
| Net Finance Costs / (Income) | 588,755 | -13.589% | 681,343 | 888,042 | 783,920 | 498,317 |
| Depreciation & Amortisation | 1,948,448 | 12.748% | 1,728,137 | 1,520,479 | 1,346,916 | 945,910 |
| Directors' Emoluments | 39,627 | 27.693% | 31,033 | 26,864 | 25,351 | 21,770 |
| 2021/12 - Final | %Chg (Compare to Final) | 2020/12 | 2019/12 | 2018/12 | 2017/12 | |
| Auditor's Opinion Status | Unqualified | -- | Unqualified | Unqualified | Unqualified | Unqualified |
Market Valuation Indicators
| 2021/12 - Final | %Chg (Compare to Final) | 2020/12 | 2019/12 | 2018/12 | 2017/12 | |
| EPS (cts) | 185.000 | 29.371% | 143.000 | 130.000 | 107.000 | 127.000 |
| DPS (cts) | 56.000 | -- | 43.000 | 39.000 | 32.000 | 38.000 |
| Dividend Payout Ratio (%) | 30.270% | -- | 30.070% | 30.000% | 29.907% | 29.921% |
| Cash flow per share ($) | 1.536 | -- | 1.007 | 1.257 | 1.169 | 1.049 |
| NBV per share ($) | 15.271 | -- | 14.413 | 12.420 | 10.894 | 10.128 |
| Remarks: | Real time quote last updated: 06/11/2024 17:59 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (K¥) | RMB 4,728,711 |
| %Change | 29.101% |
| EPS / (LPS) | RMB 1.850 |
| NBV Per Share (¥) | RMB 15.271 |